H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $15.00 price target on Briacell Therapeutics (NASDAQ: BCTX).

The analyst commented: "Our Buy rating and $15 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2037 and assign a 12% discount rate and 0% terminal value, as we believe BCTX has a novel technology platform. We currently only assume value for Bria-IMT in 3L mBC, with a 25% POS, and have not included other pipeline assets or indications in our valuation. Risks include, but are not limited to: (1) safety signals emerge with any of the company’s clinical or preclinical programs; (2) efficacy from clinical programs is lower than expected or the company’s studies do not achieve statistical significance; (3) greater than expected commercial competition for any of the company’s programs, given other treatments on the market or in development; (4) regulatory concerns or decisions related to BriaCell's assets; (5) financing requirements for the business (we assume ~$297M additional financing needed through 2037 and additional capital needed in 2025) and (6) intellectual property protection."

For an analyst ratings summary and ratings history on Briacell Therapeutics click here. For more ratings news on Briacell Therapeutics click here.

Shares of Briacell Therapeutics closed at $0.98 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy